Prediction of tumor response by FDG-PET: comparison of the accuracy of single and sequential studies in patients with adenocarcinomas of the esophagogastric junction
- First Online:
- 176 Downloads
Positron-emission-tomography with the glucose analog fluorodeoxyglucose (FDG-PET) has shown encouraging results for prediction of tumor response to chemotherapy. However, there is no consensus as to what time after initiation of therapy FDG-PET should be performed. To address this question we studied the time course of changes in tumor FDG-uptake in patients with locally advanced adenocarcinomas of the esophagogastric junction (AEG) treated with preoperative chemotherapy.
Twenty-four patients with AEG were included and underwent FDG-PET prior to therapy (PET1), 2 weeks after initiation of therapy (PET2), and preoperatively (PET3). Tumor metabolic activity was assessed by standardized uptake values (SUV) and correlated with histopathologic response and patient survival.
Baseline tumor SUV was 8.3 ± 3.5 and decreased to 5.0 ± 1.8 at PET2 (p < 0.0001). At PET3 there was further decrease to 3.5 ± 1.9 (p < 0.0001). The relative decrease of tumor FDG-uptake from PET1 to PET2 and from PET1 to PET3 were both significantly correlated with histopathologic response. Reduction of tumor SUV from PET1 to PET2 was significantly correlated with survival (p = 0.03) and there was a similar trend for changes from PET1 to PET3 (p = 0.09). In contrast, absolute SUVs did not demonstrate a significant correlation with histopathological response or patient survival at any of the studied time points.
In patients with AEG, relative changes in tumor FDG uptake are better predictors for treatment outcome than absolute SUVs. Metabolic changes within the first 2 weeks of therapy are at least as efficient for prediction of histopathologic response and patient survival as later changes.
Keywords18F-FDG-PET Oncology Neoadjuvant chemotherapy Esophageal cancer Therapy response
- 7.Cunningham D, Allum W, Stenning S, Weeden S. Perioerative chemotherpy in operable gastric and lower oesophageal cancer: final results of a randomised, controlled trial (the MAGIC Trial, ISRCTN 93793971). Proc Am Soc Clin Oncol 2005;abstract 4001.Google Scholar
- 9.Ancona E, Ruol A, Santi S, Merigliano S, Sileni VC, Koussis H, et al. Only pathologic complete response to neoadjuvant chemotherapy improves significantly the long term survival of patients with resectable esophageal squamous cell carcinoma: final report of a randomized, controlled trial of preoperative chemotherapy versus surgery alone. Cancer 2001;91:2165–74.PubMedCrossRefGoogle Scholar
- 10.Darnton SJ, Archer VR, Stocken DD, Mulholland PJ, Casson AG, Ferry DR. Preoperative mitomycin, ifosfamide, and cisplatin followed by esophagectomy in squamous cell carcinoma of the esophagus: pathologic complete response induced by chemotherapy leads to long-term survival. J Clin Oncol 2003;21:4009–15.PubMedCrossRefGoogle Scholar
- 20.Levine E, Farmer M, Clark P, Mishra G, Ho C, Geisinger KR, et al. Predictive value of 18-fluorodeoxyglucose positron emission tomography (F-18-FDG-PET) in the identification of response to chemoradiation therapy for the treatment of locally advanced esophageal cancer. Ann Surg 2006;243:472–8.PubMedCrossRefGoogle Scholar
- 21.Duong CP, Hicks RJ, Weih L, Thompson A, Williams D, Thomas RJS, et al. FDG-PET status following chemoradiotherapy provides high management impact and powerful prognostic stratification in oesophageal cancer. Eur J Nucl Med Mol Imaging 2006;33:770-81.Google Scholar
- 23.Ott K, Dittler H, Helmberger H, et al. Preoperative chemotherapy of high dose 5-FU (HDFU) + folinic acid (HDFA) + biweekly cisplatin without (group A) or with palcitaxel (group B) in patients with locally advanced adenocarcinomas of the esophagus. Proc Am Soc Clin Oncol 2000;19:(abstract 1122).Google Scholar